Cancer patients, particularly those undergoing chemotherapy, are at increased risk of developing HUS. This can be due to several factors:
Chemotherapy drugs such as mitomycin C, cisplatin, and gemcitabine are known to induce HUS. Some cancers, such as gastric and pancreatic cancers, are directly associated with a higher incidence of HUS. Cancer treatments can suppress the immune system, making patients more susceptible to infections that can trigger HUS.
